This article is more than 5 years old. Information may no longer be current.
Prostate cancer expert named co-chair of NCI committee
Click Here to Manage Email Alerts
Wm. Kevin Kelly, DO, has been elected to serve as the medical oncology co-chair on the NCI Genitourinary Cancers Steering Committee.
This committee promotes and steers phase 2 and phase 3 clinical trials in genitourinary cancers to improve clinical and translational research.
“It is a privilege to serve as a co-leader on the NCI Genitourinary Task force that has the responsibility in guiding the next generation of clinical trials to improve the lives and suffering of patients with genitourinary tumors,” Kelly, who is the leader of the prostate cancer program and associate director of clinical research at the Sidney Kimmel Cancer Center at Jefferson Health, said in a press release.
Kelly, who is also director of the division of solid tumor oncology, has helped grow the Sidney Kimmel Cancer Center’s clinical trial program. He also has contributed to drug development and the identification of biomarkers for the treatment of patients with prostate and bladder cancers.
“This is a well-deserved honor for Dr. Kelly, who has been instrumental in bringing new therapeutic interventions to the forefront in the prostate cancer field,” Karen Knudsen, PhD, director of the Sidney Kimmel Cancer Center said in the release. “As one of the few cancer centers — and the only in Philadelphia — to have an NCI-designated Prostate Cancer Program of Excellence, Dr. Kelly has distinguished himself in the ability to serve the specialized needs of a large city that is challenged by a high incidence of and mortality from prostate cancer. He now brings this leadership to the national level.”